News
12 August 2019
Cambridge Cognition expands further into Chinese market and initial university contract
Cambridge Cognition is pleased to announce its expansion into the Chinese market with the Company’s Cambridge Neuropsychological Test Automated Battery (“CANTAB”) computerised assessments. This move strengthens the Company’s global position, having announced a major opportunity in India earlier this year.
Read on
19 July 2019
New Commercial Partnership and Further Scientific Validation for NeuroVocalix
Cambridge Cognition is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer’s conference.
Read on
1 July 2019
Cambridge Cognition appoints Non-Executive Director
Cambridge Cognition today announced the appointment of Debra Leeves as a Non-Executive Director with immediate effect.
Read on
24 May 2019
NHS Bedfordshire CCG rolls out CANTAB Mobile to 50 practices following successful pilot study
We’re pleased to announce that NHS Bedfordshire Clinical Commissioning Group (CCG) is introducing our iPad-based memory assessment tool into 50 general practices.
Read on
10 May 2019
CANTAB Research Grant 2019 - Results
The results of the 2019 CANTAB Research Grant are in! Once again we were overwhelmed by the quality of applications we received – which made it a tough job for our judging panel to narrow the research proposals down.
Read on
19 March 2019
Cambridge Cognition wins significant new digital health contract worth £1.3m
Cambridge Cognition has announced a significant new contract providing digital health technologies to a major pharmaceutical company for application in a clinical stage development programme.
